Thromboembolism prophylaxis in chronic atrial fibrillation: Practice patterns in community and tertiary-care hospitals

Stroke

Volumn 28, Issue 1, 1997, Pages 72-76

  Munschauer, F E ^a,b   Priore, R L ^a   Hens, M ^a   Castilone, A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b BUFFALO GENERAL HOSPITAL   (United States)

Author keywords

anticoagulants; atrial fibrillation; hospitalization; quality of health care; stroke prevention; warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; PRIORITY JOURNAL; STROKE; THROMBOEMBOLISM;

EID: 0031015882     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.28.1.72     Document Type: Article

References (23)

1. Feinberg M, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution and gender in patients with atrial fibrillation. Arch Intern Med. 1995;155:469-473.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med. 1987;147:1561-1564.
3. Petersen P, Godtfredsen J, Boysen G, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1: 175-179.
4. The BAATAF investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
5. The SPAF Investigators. The Stroke Prevention in Atrial Fibrillation study: final results. Circulation. 1991;84:527-539.
6. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C, the CAFA Investigators. Canadian Atrial Fibrillation Anticoagulation Study. J Am Coll Cardiol. 1991;18:349-355.
7. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, Rickles FR, Shabetai R, Deykin D. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406-1412.
8. SPAF Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet. 1994;343:687-691.
9. SPAF Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-638.
10. SPAF Investigators. Predictors of thromboembolism in atrial fibrillation, I: clinical features of patients at risk. Ann Intern Med. 1992;116:1-5.
11. SPAF Investigators. Predictors of thromboembolism in atrial fibrillation, II: echocardiographic features of patients at risk. Ann Intern Med. 1992;116:6-12.
12. Wintzen AR, deJonge H, Loeliger EA, Bots GTAM. The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol. 1984;16:553-558.
13. Kase CS, Robinson RK, Stein RW, DeWitt LD, Hier DB, Harp DL. Anticoagulant-related intracerebral hemorrhage. Neurology. 1985; 35:943-948.
14. Albers GW. Intensity of anticoagulant treatment and risk of intrace-rebral hematoma. Stroke. 1990; 21:1758, Letter.
15. Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation. Chest. 1992;102(suppl):426S-433S.
16. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest. 1995; 108(suppl):352S-359S.
17. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154; 1449-1457.
18. Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A, Patwardhan NA. Changing clinical practice: prospective study of the impact of continuing medical education and quality assurance programs on use of prophylaxis for venous thromboembolism. Arch Intern Med. 1994;154:669-677.
19. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Arch Intern Med. 1994;154:1945-1953.
20. Chang HJ, Bell JR, Deroo DB, Kirk JW, Wasson JH. Physician variation in anticoagulating patients with atrial fibrillation. Arch Intern Med. 1990;150:83-86.
21. Kutner M, Nixon G, Silverstone F. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med. 1991;151:1950-1953.
22. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-1845.
23. Lancaster TR, Singer DE, Sheehan MA, Oertel LB, Maraventano SW, Hughes RA, Kistler JP. The impact of long-term warfarin therapy on quality of life: evidence from a randomized trial. Arch Intern Med. 1991;151:1944-1949.